Global Cervial Dysplacia Market, By Diagnosis Type [Diagnosis Test (HPV Test, Pap Smear Test, Biopsy Test) and Diagnostic Device (Colonoscpe) ], By End User (Hospitals, Diagnostic Centers, and Ambulatory Surgical Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 675 Mn in 2023, and is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on adopting growth strategies such as development of innovative drug therapy for the treatment of cervical dysplasia. For instance, on March 1, 2021, INOVIO, a biotechnology company, announced that it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of two ongoing pivotal, randomized, double-blind, multi-center, placebo-controlled, Phase 3 trials (REVEAL 1 and REVEAL 2) evaluating the safety, tolerability and efficacy of VGX-3100 to treat cervical dysplacia.
Global Cervial Dysplacia Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of things from one place to another.
COVID-19 had negative impact on the global cervial dysplacia market, as patients could not visit physicians for the treatment of the disease due to lockdown was imposed globally.
Global Cervial Dysplacia Market: Key Developments
On February 24, 2021, INOVIO, a biotech company, and QIAGEN, a provider of sample and assay technologies for molecular diagnostics, expanded collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia.
Browse 26 Market Data Tables and 25 Figures spread through 145 Pages and in-depth TOC on “Global Cervial Dysplacia Market”- Forecast to 2030, Global Cervial Dysplacia Market, By Diagnosis Type [Diagnosis Test (HPV Test, Pap Smear Test, Biopsy Test) and Diagnostic Device (Colonoscpe) ], By End User (Hospitals, Diagnostic Centers, and Ambulatory Surgical Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cervical-dysplasia-diagnostic-market-1486
Key Takeaways of the Global Cervical Dysplacia Market:
- Global cervial dysplacia market is expected to exhibit a CAGR of 7.3% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global cervial dysplacia market.
- Among diagnosis type, the diagnostic test segment is expected to hold a dominant position in the global cervial dysplacia market during the forecast period
- Among region, North America is expected to be the dominant region in the global cervial dysplacia market, owing to increasing prevalence of cervical dysplacia in North America. For instance, according to the data published by the Center for Disease Control and Prevention (CDC) on June 8, 2023, about 11,500 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer every year in the U.S
- Major players operating in the global cervial dysplacia market are Roche, Qiagen, Abbott Laboratories, BD, Hologic, Seegene, Arbor Vita, Femasys, and Cooper Surgical.
